• Global H1 FY26 sales grew to AUD $4.2 million, with the U.S. market showing strong momentum (+17% YoY)
• Validated 'Hyper-Immune' platform is moving into high-value clinical targets like C. diff (IMM-529) with estimated peak U.S. sales of US$400 million
• Cash (AUD $10.0 million) to fund operating activities for 23.52 months

Immuron Ltd, a commercial-stage biopharmaceutical company, reported its strategic update and half-year financial results for FY26. The company's core strength lies in its 'Hyper-Immune' platform, which allows it to program cows to produce high levels of specific polyclonal antibodies. This platform is versatile and is being used to target various infectious diseases, including traveler's diarrhea (Travela®) and Clostridioides difficile (IMM-529). Immuron has de-risked its supply chain by sourcing all colostrum from Australia or New Zealand, which are Category 1 countries with negligible risk of BSE. The company has also secured scalable partnerships with dairy farms in Australia and is producing its products under Good Manufacturing Practice (GMP) standards. Immuron's financial highlights include global H1 FY26 sales of AUD $4.2 million, up 5% year-over-year, with the U.S. market showing strong momentum (+17% YoY). The company has a cash position of AUD $10.0 million, equivalent to 23.52 months of operating activities. Immuron is planning growth in profitability of its Hyper-Immune products, targeting improvement in EBITDX (ex-R&D) in H2 FY26. The company's clinical development pipeline includes Travela® for traveler's diarrhea, IMM-529 for Clostridioides difficile, and a new project (IMM-986) targeting Vancomycin Resistant Enterococci (VRE).

Immuron is planning growth in profitability of its Hyper-Immune products, targeting improvement in EBITDX (ex-R&D) in H2 FY26. The company will seek partners to advance the clinical development of Travela® (IMM-124E) and IMM-529.